Symptomatic adrenal insufficiency during inhaled corticosteroid treatment

L Patel, J K Wales, M S Kibirige, A A Massarano, J M Couriel, P E Clayton

Abstract
Symptomatic adrenal insufficiency, presenting as hypoglycaemia or poor weight gain, may occur on withdrawal of corticosteroid treatment but has not previously been reported during inhaled corticosteroid treatment. This case series illustrates the occurrence of clinically significant adrenal insufficiency in asthmatic children while patients were on inhaled corticosteroid treatment and the unexpected modes of presentation. General practitioners and paediatricians need to be aware that this unusual but acute serious complication may occur in patients treated with inhaled corticosteroids.

(Keywords: adrenal insufficiency; inhaled corticosteroid; asthma; hypoglycaemia)

Impaired linear growth and hypothalamic–pituitary–adrenal (HPA) suppression on biochemical testing are recognised systemic effects of inhaled corticosteroids (ICS) in doses ≤ 400 μg/day.1 2 In addition, a Cushingoid appearance with central obesity and fatigue have been reported with high doses.3 4 Features of adrenal insufficiency, such as hypoglycaemia and weight loss, may occur on withdrawal of exogenous ICS treatment.5 Despite HPA suppression, symptomatic adrenal insufficiency does not occur during treatment with pharmacological doses (exceeding physiological cortisol secretion) and has not previously been reported during treatment with subpharmacological doses as delivered by the inhaled route. The aim of this case series is to describe the occurrence of clinically significant adrenal insufficiency in association with HPA suppression in asthmatic children while patients were on ICS treatment, and the unexpected modes of presentation.

Case series

CLINICAL FEATURES AT PRESENTATION

Between January 1997 and March 1999, eight children (five boys, three girls; median age 6.9 years, range 4.5–10.0) with varied presentations came to the attention of specialists at three paediatric endocrine services in the north of England. They were identified on clinical assessment and biochemical testing to have adrenal insufficiency and HPA suppression. Table 1 summarises their clinical features at presentation and results of biochemical tests. All had mild to moderately severe asthma, were managed by general practitioners or general paediatricians, had responded clinically to ICS treatment, and were deemed to be compliant with their treatment. Case 4 had coexisting allergic rhinitis and had received budesonide nasal spray 400 μg/day for six months. The remaining cases had not received corticosteroids by any other route in the six months prior to presentation. None had received prolonged courses of systemic corticosteroids at any time. No patient had hyperpigmentation.

Cases 1 and 2 presented acutely with hypoglycaemia while receiving treatment with inhaled fluticasone. Their treatment had not been suddenly withdrawn prior to presentation. Neither patient had an acute intercurrent illness nor other stressful event at the time of presentation. Metabolic and other endocrine causes of hypoglycaemia were excluded by biochemical investigations (normal values of urine organic acid profile and blood acyl carnitine, insulin and C peptide at the time of hypoglycaemia, growth hormone, thyroxine, and TSH) and subsequent progress.

The presentation in the remaining patients was insidious. Notable features in cases 3–6 were poor weight gain while patients were receiving treatment with inhaled fluticasone. Their treatment had not been suddenly withdrawn prior to presentation. Neither patient had an acute intercurrent illness nor other stressful event at the time of presentation. Metabolic and other endocrine causes of hypoglycaemia were excluded by biochemical investigations (normal values of urine organic acid profile and blood acyl carnitine, insulin and C peptide at the time of hypoglycaemia, growth hormone, thyroxine, and TSH) and subsequent progress.

INVESTIGATION RESULTS AT PRESENTATION

HPA suppression was identified by: (1) low basal plasma cortisol (all cases); and (2) impaired response to standard dose ACTH (Synacthen) test (cases 1–5, 8) or low 24 hour urine cortisol metabolites (cases 6, 7) (table 1). The pituitary–adrenal axis was unresponsive to stimulation with corticotrophin releasing factor (CRF) at presentation in cases 1, 3, and 4 (plasma cortisol <20 nmol/l and plasma
SDST, standard dose Synacthen (ACTH) test (criterion for normal response is peak plasma cortisol >500 nmol/l).

*0700–0900 plasma cortisol (normal range 250–700 nmol/l).

Patients who had ultrasound examination of the abdomen, the adrenal glands appeared normal in cases 1, 3, and 7 but could not be identified in case 4. Autoantibody screen was negative in all.

**MANAGEMENT AND PROGRESS**

The dose of ICS at presentation did not exceed that recommended in step 3 of the British Thoracic Society Guidelines in seven of these eight cases (case 8 was the exception). However, only two patients (cases 6 and 7) were receiving medication within the licenced prescription (beclomethasone 400 µg/day, fluticasone 500 µg/day, and budesonide 400 µg/day). Case 2 had received fluticasone 1500 µg/day for four weeks, 1000 µg/day for four weeks, and 500 µg/day for eight weeks prior to presentation. We are not aware of other patients receiving higher doses of ICS than those mentioned in table 1.

The management of adrenal insufficiency included: (1) informing parents about a potential adrenal crisis, management of acute stressful events, and precautions necessary to prevent this emergency; and (2) training parents to manage an acute adrenal crisis and providing open access to the hospital accident and emergency department. Daily hydrocortisone replacement (physiological dose 12 mg/m²/day orally, with two thirds of the dose in the morning and one third in the evening) was indicated in patients who presented with hypoglycaemia (cases 1 and 2) and those with no adrenocortical reserve (cases 3 and 4, and case 7 for 18 months). In the remaining patients, hydrocortisone replacement was reserved for acute stressful events. Patients were reviewed at four to eight weekly intervals and an attempt was made to gradually reduce the dose of ICS while simultaneously maintaining adequate control of asthma symptoms. Biochemical tests of HPA axis function were repeated after successful reduction in dose of ICS or gradual withdrawal of treatment. Any ICS treatment and hydrocortisone replacement were withheld for 24 hours prior to testing.

Normal ACTH test responses and 24 hour urine cortisol metabolites were obtained in four cases after: (1) gradual withdrawal of ICS (case 7 over 18 months when hydrocortisone was also discontinued) or with salmeterol (case 7 over 18 months when hydrocortisone was also discontinued) or with addition of salmeterol (case 6 from beclomethasone 600 µg/day to budesonide 200 µg/day over six months) or with salmeterol (case 5 from beclomethasone 600 µg/day to budesonide 400 µg/day over 18 months).

### Table 1 Clinical features of adrenal insufficiency in eight patients identified to have hypothalamic–pituitary–adrenal suppression during inhaled corticosteroid treatment

<table>
<thead>
<tr>
<th>Case, sex</th>
<th>Clinical features at presentation (age)</th>
<th>Height in cm (SDS)</th>
<th>Weight in kg (SDS)</th>
<th>HPA function at presentation (plasma cortisol in nmol/l)</th>
<th>Inhaled corticosteroid, daily dose (dose/m²/day) device; duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>1, M</td>
<td>Acute: unconscious, plasma cortisol 0.9 mmol/l (4.5 y)</td>
<td>6.3</td>
<td>18.6 (−1.1)</td>
<td>Plasma cortisol 100 at 0800*, SDST peak 200</td>
<td>Fluticasone 500 µg/day; (780 µg/m²/day) volumatic; 6 mth</td>
</tr>
<tr>
<td>2, F</td>
<td>Acute: drowsy, disoriented and headache for 24 h, plasma cortisol 0.7 mmol/l. Also had poor growth in height and weight for 12 mth (5.8 y)</td>
<td>4.8</td>
<td>10.0 (−0.7)</td>
<td>Plasma cortisol 30 at 0900*, SDST peak 30</td>
<td>Budesonide 400 µg/day; (570 µg/m²/day) nebulhaler; 15 mth, followed by fluticasone 500 µg/day (705 µg/m²/day) volumatic; 4 mth</td>
</tr>
<tr>
<td>3, M</td>
<td>Insidious: weight loss and thinness for 3 mth (4.5 y)</td>
<td>5.8</td>
<td>10.0 (−1.3)</td>
<td>Plasma cortisol 100 at 0830*, SDST peak 20</td>
<td>Fluticasone 500 µg/day; (770 µg/m²/day) volumatic; 6 mth</td>
</tr>
<tr>
<td>4, M</td>
<td>Insidious: poor growth in height and weight for 2 y (8.0 y)</td>
<td>7.0</td>
<td>119.7 (−0.3)</td>
<td>Plasma cortisol &lt;20 at 0900*, SDST peak &lt;20</td>
<td>Fluticasone 500 µg/day; (610 µg/m²/day) volumatic; 4.5 y</td>
</tr>
<tr>
<td>5, M</td>
<td>Insidious: poor growth in height and weight for 12 mth (10.0 y)</td>
<td>8.0</td>
<td>114.6 (−2.4)</td>
<td>Plasma cortisol 90 at 0900*, SDST peak 300</td>
<td>Budesonide dipropionate 600 µg/day (690 µg/m²/day) dishcaler; 3 y</td>
</tr>
<tr>
<td>6, F</td>
<td>Insidious: poor growth in height and weight for 2 y (9.8 y)</td>
<td>4.2</td>
<td>97.8 (−1.5)</td>
<td>Plasma cortisol 162 at 0900*, 24 h urine cortisol metabolites (THC 380 µg, THE 70 µg) metabolites low†</td>
<td>Budesonide 400 µg/day; (505 µg/m²/day) nebulhaler; 5 y</td>
</tr>
<tr>
<td>7, M</td>
<td>Insidious: poor growth in height and hirsutism for 6 mth (5.6 y)</td>
<td>5.6</td>
<td>101.5 (−2.5)</td>
<td>Plasma cortisol &lt;20 and 30 at 0900*, 24 h urine cortisol metabolites undetectable†</td>
<td>Budesonide 400 µg/day; (595 µg/m²/day) nebulhaler; 12 mth</td>
</tr>
<tr>
<td>8, F</td>
<td>Insidious: poor growth in height and headaches for 12 mth (8.4 y)</td>
<td>6.7</td>
<td>111.5 (−1.6)</td>
<td>Plasma cortisol 33 at 0900*, SDST peak 325</td>
<td>Fluticasone 1000 µg/day; (1136 µg/m²/day) volumatic; 18 mth</td>
</tr>
</tbody>
</table>

**Legend**

<table>
<thead>
<tr>
<th>SDS</th>
<th>Height in cm (SDS)</th>
<th>Age in y</th>
<th>Weight in kg (SDS)</th>
<th>HPA function at presentation (plasma cortisol in nmol/l)</th>
<th>Inhaled corticosteroid, daily dose (dose/m²/day) device; duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.3</td>
<td>120.0 (−2.4)</td>
<td>11.3</td>
<td>137.0 (−1.2)</td>
<td>Plasma cortisol 100 at 0830*, SDST peak 200</td>
<td>Fluticasone 500 µg/day; (780 µg/m²/day) volumatic; 6 mth</td>
</tr>
<tr>
<td>4.8</td>
<td>99.6 (−1.9)</td>
<td>11.3</td>
<td>137.0 (−1.2)</td>
<td>Plasma cortisol 100 at 0830*, SDST peak 200</td>
<td>Fluticasone 500 µg/day; (780 µg/m²/day) volumatic; 6 mth</td>
</tr>
<tr>
<td>6.7</td>
<td>111.5 (−1.6)</td>
<td>10.1</td>
<td>128.0 (−1.6)</td>
<td>Plasma cortisol 33 at 0900*, SDST peak 325</td>
<td>Fluticasone 1000 µg/day; (1136 µg/m²/day) volumatic; 18 mth</td>
</tr>
<tr>
<td>8.5</td>
<td>119.5 (−1.9)</td>
<td>10.1</td>
<td>128.0 (−1.6)</td>
<td>Plasma cortisol 33 at 0900*, SDST peak 325</td>
<td>Fluticasone 1000 µg/day; (1136 µg/m²/day) volumatic; 18 mth</td>
</tr>
</tbody>
</table>

**Notes**

1. Plasma cortisol <5 pmol/l at all time points.
2. Patients receiving higher doses of ICS than those mentioned in table 1.
4. **Table 1** Clinical features of adrenal insufficiency in eight patients identified to have hypothalamic–pituitary–adrenal suppression during inhaled corticosteroid treatment.
Table 2  Growth data showing poor growth in height and weight at presentation and
subsequent catch up

<table>
<thead>
<tr>
<th></th>
<th>Before presentation</th>
<th>After follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range) time, y</td>
<td>1.0 (0.5–3.2)</td>
<td>1.7 (1.1–2.3)</td>
</tr>
<tr>
<td>Mean (SD) change in height SDS</td>
<td>−0.7 (0.5)</td>
<td>0.7 (0.5)</td>
</tr>
<tr>
<td>(p with t test)</td>
<td>(p = 0.01)</td>
<td>(p = 0.003)</td>
</tr>
<tr>
<td>Mean (SD) change in weight SDS</td>
<td>−0.7 (0.6)</td>
<td>1.1 (0.6)</td>
</tr>
<tr>
<td>(p with t test)</td>
<td>(p = 0.03)</td>
<td>(p = 0.001)</td>
</tr>
</tbody>
</table>

 Plasma cortisol 400 nmol/l and his dose of oral hydrocortisone is currently being reduced. The remaining cases have continued to require oral hydrocortisone replacement for over three years despite some alterations to their ICS treatment and salmeterol (case 1 from fluticasone 500 µg/day to budesonide 300 µg/day; case 2 from fluticasone 500 µg/day to budesonide 400 µg/day; case 4 from fluticasone 500 µg/day to budesonide 800 µg/day). Catch up growth in weight and height (table 2) was observed in all patients: with hydrocortisone replacement (cases 1–4, 7), ICS withdrawal (cases 3, 7, and 8) and change in ICS preparation (cases 5 and 6).

Discussion
As exogenous corticosteroids cause greatest suppression of ACTH secretion, it may be difficult to differentiate from isolated ACTH or CRF deficiency, particularly when the corticosteroid dose is in the normal range. Not only are the latter extremely uncommon, but the time course of events in relation to ICS treatment in our patients makes isolated ACTH or CRF deficiency less likely. The absence of troublesome asthma symptoms when growth was impaired and subsequent catch up growth after the diagnosis and management of adrenal insufficiency excludes uncontrolled asthma as an explanation for the poor growth and is highly suggestive of reversal of adrenal insufficiency induced by ICS treatment. Impaired growth in height is a feature of Cushing’s syndrome secondary to excess exogenous ICS, a recognised systemic effect of conventional doses of ICS and also a sign of adrenal insufficiency. However, the key to differentiation is increased or normal weight gain in the former and poor weight gain/weight loss in adrenal insufficiency.

This case series highlights an unrecognised paradoxical complication during ICS treatment with doses within current recommended guidelines. All patients were symptomatic but the presenting features were varied and unexpected: features of adrenal insufficiency (poor weight gain, hypoglycaemia) predominated over well known peripheral effects of excess exogenous corticosteroids (iatrogenic Cushing’s syndrome). Our observations and the large reported range of effects on linear growth and HPA function, and occurrence of adverse effects with doses of ICS normally considered to be safe illustrate variations in individual sensitivity to corticosteroids. In addition, corticosteroid sensitivity is also likely to vary between different target tissues, and a lack of correspondence between different corticosteroid effects has been reported in healthy and non-asthmatic adults. Differential tissue sensitivity has also been proposed as an explanation for those patients with asthma who fail to respond to corticosteroid treatment but who have systemic effects. In our cases, it is likely that the systemic bioavailability of ICS was sufficient to suppress the HPA axis but not adequate enough to provide physiological corticosteroid replacement and thus prevent symptoms of hypoadrenalism. This, along with differential tissue sensitivity explains the predominant features of adrenal insufficiency, including hypoglycaemia, listlessness, and poor weight gain with poor growth in height.

Adrenal insufficiency, irrespective of cause, is one of the acute life threatening emergencies in paediatric practice. General practitioners and paediatricians need to be aware that it may occur in patients treated with ICS and of the unusual modes of presentation to provide timely management. Although the daily dose of ICS for seven of the eight cases might not be considered excessive, all patients were small (weight and height SD scores <0) and consequently their dose per m² body surface area was relatively higher. Evidence based guidelines with doses of ICS recommended according to body surface area are needed. The differing potencies of the various ICS preparations, including the widely accepted 2:1 ratio between fluticasone and other ICS preparations, also needs to be taken into account. We emphasise that the distribution of the ICS preparations used in our small series should not be extrapolated to that used in the general population. Furthermore, as our patients had well controlled asthma, an attempt should have been made to reduce their dose of ICS treatment before presentation. Failure to do so was a possible risk factor for adrenal suppression. Alternative treatments such as salmeterol and leukotriene receptor antagonists may have a role in patients who do not respond to corticosteroid treatment. When using ICS in the management of asthma, there is a clear need to be ever cautious, as a few children as outlined in this series can get serious systemic effects, such as hypoglycaemia secondary to adrenal insufficiency, that cannot readily be predicted. As growth and weight failure was an important feature of our cases, we must emphasise the importance of growth monitoring for all children on ICS. If growth failure is detected, adrenal insufficiency should be considered and investigated with dynamic tests of adrenal function.


www.archdischild.com
Symptomatic adrenal insufficiency during inhaled corticosteroid treatment


Commentary

When inhaled corticosteroid (ICS) therapy was introduced to clinical practice, it was at a time when the therapeutic options for asthma prophylaxis were limited to theophylline and sodium cromoglycate, and many asthmatic children were still on regular oral corticosteroids. Early searches for side effects from ICS gave uniformly reassuring results, and the new treatment was welcomed as a safe and effective alternative to oral prednisolone, even when high dose ICS was necessary. The adrenal atrophy reported at autopsy in asthmatic children who had died while on ICS was widely attributed to systemic bioavailability of ICS. In two cases there was acute hypoglycaemia, and the report was discounted.

In two cases there was acute hypoglycaemia, not apparently caused by the sudden withdrawal of ICS, though this is the explanation that springs most readily to mind. These two cases are particularly worrying, suggesting that acute adrenal insufficiency can occur even when the child is still taking the exogenous corticosteroid that caused the adrenal insufficiency in the first place. Clearly, paediatricians will have to be vigilant in investigating asthmatic children with disturbed consciousness, unusual behaviour, or autonomic symptoms suggestive of hypoglycaemia. In addition, given the lingering suspicion that the ICS treatment must have been discontinued (if not indeed discontinued), prescribers of ICS must emphasise the importance of compliance, and ensure that when treatment is successful, it is stepped down gradually rather than stopped suddenly.

The other cases presented insidiously, five with impaired growth over periods ranging from six months to two years. In only one did the ICS dose exceed current recommendations.

The authors are quite clear that the asthma was well controlled in these children, and this might have played a part in ensuring the systemic absorption of what are unremarkable doses of ICS. The systemic effects of budesonide and fluticasone reflect mainly lung bioavailability, and it has been shown that the systemic bioavailability of ICS is greater in subjects with healthy airways than in asthmatics. Thus, if in these cases the doses of ICS were greater than was strictly necessary, enhanced systemic absorption might have ensued, although a logical extension of this argument would be that perfect control is an undesirable end point for ICS therapy.

Perhaps we should have advised against the inclusion of case 7, whose presenting features included hirsutism, hardly a feature of simple adrenal suppression. His body mass index was rather better than in the others, and he may well have had some other endocrine abnormality. However, none was found and on balance we decided that all eight cases should be included.

We can only guess at the prevalence of clinically significant adrenal suppression in children on ICS, but clearly we can no longer claim that it is non-existent. Nor can we be sure that the distribution of the individual corticosteroid molecules used by these children is anything other than a chance phenomenon. The authors are rightly cautious in refusing to comment. But it can hardly pass unnoticed that only one of these eight children was on beclometasone,

www.archdischild.com
whereas the others were on what are sometimes described as second or even third generation ICS. Beclomethasone was the first and is still the most widely used ICS in the UK. In England in 1998, 8.43 million NHS prescriptions were filled for beclomethasone, compared to only 1.88 million for budesonide and 1.54 million for fluticasone. We too are cautious in our interpretation of these proportions, but await with interest further reports of ICS related adrenal suppression.

So, what are the conclusions to be drawn from this report? In our current state of knowledge, it would be quite wrong to suggest a major change in established practice. ICS treatment has been of immense value to literally millions of children, and other anti-asthma therapy is best regarded as steroid sparing rather than a true alternative to ICS. Nevertheless, we should review our practice and pay more attention to existing recommendations on the importance of stepping down as well as stepping up ICS, and, as ever, we must be constantly vigilant for unforeseen side effects of even the best established drugs. Whatever else we do, we must not panic and endanger the lives and wellbeing of the countless children whose respiratory and endocrine systems co-exist happily on ICS.

GEORGE RUSSELL
Department of Child Health, University of Aberdeen, UK


17 http://www.doh.gov.uk/pdfs/pcs98.pdf


www.archdischild.com

7th European Forum on Quality Improvement in Health Care

21–23 March 2002
Edinburgh, Scotland

We are delighted to announce this forthcoming conference in Edinburgh. Authors are invited to submit papers (call for papers closes on Friday 5 October 2001) and delegate enquiries are welcome.

The themes of the Forum are:
- Leadership, culture change, and change management
- Achieving radical improvement by redesigning care
- Health policy for lasting improvement in health care systems
- Patient safety
- Measurement for improvement, learning, and accountability
- Partnership with patients
- Professional quality: the foundation for improvement
- Continuous improvement in education and training
- People and improvement.

Presented to you by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA). For more information contact: quality@bma.org.uk or look at the website www.quality.bmjpg.com. Tel: +44 (0)20 7383 6409; fax: +44 (0)20 7373 6869.
Symptomatic adrenal insufficiency during inhaled corticosteroid treatment

L Patel, J K Wales, M S Kibirige, A A Massarano, J M Couriel and P E Clayton

Arch Dis Child 2001 85: 330-334
doi: 10.1136/adc.85.4.330

Updated information and services can be found at:
http://adc.bmj.com/content/85/4/330

These include:

References
This article cites 26 articles, 9 of which you can access for free at:
http://adc.bmj.com/content/85/4/330#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Adrenal disorders (45)
- Drugs: respiratory system (111)
- Child health (3922)
- Asthma (369)
- Diabetes (339)
- Immunology (including allergy) (2018)
- Metabolic disorders (761)

Notes